Signals of Change in the Management of Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, inflammatory skin disease that effects up to 18% of children and up to 10% of adults and can have a substantial negative impact on the quality of life (QoL) of patients and their families. Its management is challenging at any age, with patients and caregivers often becoming overwhelmed by the chronic and relapsing nature of AD. Establishing disease severity is essential to inform treatment decisions, as is information on new clinical trial data for therapies such as oral Janus kinase (JAK) inhibitors. Thus, education that provides tools to establish disease severity and information on the development of new agents is warranted in order to mitigate the clinical and QoL impact of AD.

This enduring material blends faculty presentation and discussion to assist learners in applying clinical tools to establish disease severity, translating how new agents will impact clinical practice, and integrating patient preferences and treatment goals into shared decision-making (SDM).

- Learning Objectives -

At the end of this CE activity, participants should be able to:
- Apply clinical tools to establish disease severity to inform treatment decisions in patients with AD.
- Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
- Integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify clinical tools to establish disease severity to inform treatment decisions in patients with AD.
- Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
- Explain how to integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.